Erschienen in:
15.03.2021 | Original Paper
The utility of incisional vacuum-assisted closure in surgical Management of Hidradenitis Suppurativa: a retrospective cohort study
verfasst von:
Ledibabari M. Ngaage, Yinglun Wu, Shealinna Ge, Michael Ha, Arthur J. Nam, Yvonne M. Rasko
Erschienen in:
European Journal of Plastic Surgery
|
Ausgabe 5/2021
Einloggen, um Zugang zu erhalten
Abstract
Background
Wide local excision is the gold standard treatment for severe hidradenitis suppurativa but remains challenging due to high rates of complications and recurrence. Incisional vacuum-assisted closure devices are powerful adjuncts to enhance postoperative wound healing.
Methods
We performed a retrospective cohort study of all patients who underwent surgical excision for hidradenitis over a 10-year period. The cohort was divided into patients who received standard sterile dressings and those who received incisional vacuum-assisted closure. The primary outcomes were surgical site complications and recurrence of disease. The data were analysed using univariate and multivariable logistic regression analyses.
Results
We included 79 patients; patients had multifocal disease which resulted in 220 operative sites. Fifty-eight operative sites (26%) received vacuum-assisted closure and 162 (74%) did not. Operative sites with vacuum-assisted closure were larger (140 vs 60 cm2, p < 0.001) and had longer operations (72 vs 46 min, p < 0.001), and longer hospital stays (6 vs 0 days, p < 0.001). When adjusted for preoperative and operative factors, vacuum-assisted closure did not significantly decrease the odds of experiencing a complication (OR 0.70, p = 0.409) but, however, did significantly reduce the odds of disease recurrence (OR 0.28, p = 0.020).
Conclusions
The use of vacuum-assisted closure does not alter risk of complications but may play a role in preventing hidradenitis recurrence. Given the high costs associated with long hospitalisations, more cost-effective solutions should be investigated, such as home vacuum-assisted closure therapy.
Level of evidence: Level III, therapeutic study.